Gabrielle P Dailey, Christopher A Rabiola, Gangjun Lei, Junping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Melissa Gajda, Amy C Hobeika, Amanda Summers, Robert D Marek, Michael A Morse, Herbert K Lyerly, Erika J Crosby, Zachary C Hartman
{"title":"Vaccines targeting <i>ESR1</i> activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer.","authors":"Gabrielle P Dailey, Christopher A Rabiola, Gangjun Lei, Junping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Melissa Gajda, Amy C Hobeika, Amanda Summers, Robert D Marek, Michael A Morse, Herbert K Lyerly, Erika J Crosby, Zachary C Hartman","doi":"10.1080/21645515.2024.2309693","DOIUrl":null,"url":null,"abstract":"<p><p>ER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (<i>ESR1)</i>, which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment inevitably results in therapeutic resistance, which can occur through the emergence of gain-of-function mutations in <i>ESR1</i>. The central importance of <i>ESR1</i> and development of mutated forms of <i>ESR1</i> suggest that vaccines targeting these proteins could potentially be effective in preventing or treating endocrine resistance. To explore the potential of this approach, we developed several recombinant vaccines encoding different mutant forms of <i>ESR1</i> (<i>ESR1</i>mut) and validated their ability to elicit <i>ESR1</i>-specific T cell responses. We then developed novel <i>ESR1</i>mut-expressing murine mammary cancer models to test the anti-tumor potential of <i>ESR1</i>mut vaccines. We found that these vaccines could suppress tumor growth, <i>ESR1</i>mut expression and estrogen signaling in vivo. To illustrate the applicability of these findings, we utilize HPLC to demonstrate the presentation of <i>ESR1</i> and <i>ESR1</i>mut peptides on human ER+ BC cell MHC complexes. We then show the presence of human T cells reactive to <i>ESR1</i>mut epitopes in an ER+ BC patient. These findings support the development of <i>ESR1</i>mut vaccines, which we are testing in a Phase I clinical trial.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10857653/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2309693","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
ER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment inevitably results in therapeutic resistance, which can occur through the emergence of gain-of-function mutations in ESR1. The central importance of ESR1 and development of mutated forms of ESR1 suggest that vaccines targeting these proteins could potentially be effective in preventing or treating endocrine resistance. To explore the potential of this approach, we developed several recombinant vaccines encoding different mutant forms of ESR1 (ESR1mut) and validated their ability to elicit ESR1-specific T cell responses. We then developed novel ESR1mut-expressing murine mammary cancer models to test the anti-tumor potential of ESR1mut vaccines. We found that these vaccines could suppress tumor growth, ESR1mut expression and estrogen signaling in vivo. To illustrate the applicability of these findings, we utilize HPLC to demonstrate the presentation of ESR1 and ESR1mut peptides on human ER+ BC cell MHC complexes. We then show the presence of human T cells reactive to ESR1mut epitopes in an ER+ BC patient. These findings support the development of ESR1mut vaccines, which we are testing in a Phase I clinical trial.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.